<DOC>
	<DOCNO>NCT01142856</DOCNO>
	<brief_summary>The purpose study determine safety inject mesenchymal stem cell intraspinal delivery treatment ALS .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Treatment Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>A single patient safety study harvesting , expand ex vivo inject autologous mesenchymal stem cell ( MSC 's ) subarachnoid space patient amyotrophic lateral sclerosis ( ALS ) . Cells isolate adipose tissue subcutaneous biopsy expand use FDA-approved protocol . They inject lumbar puncture cerebrospinal fluid . Injection complete in- patient clinical research unit ( CRU ) . patient follow two year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>age great 18 year , female , must menopausal hysterectomy resident citizen United States history chronic onset progressive motor weakness able comply protocol requirement provide write consent renal disease ( Creatine &gt; 2.0 ) active systemic disease clinically significant abnormality prestudy laboratory evaluation clinically significant medical condition ( e.g. , within 6 month baseline , myocardial infarct , angina pectoris , and/or congestive heart failure ) , opinion investigator , would compromise safety patient history cancer include melanoma exception localize skin cancer ( evidence metastasis , significant invasion , reoccurrence within 3 year baseline ) . use investigational drug within 30 day baseline visit tracheostomy Beck 's Depression Inventory score &gt; 16</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>